Century Therapeutics (IPSC) Cash from Investing Activities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash from Investing Activities data on file, last reported at -$112.6 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 503.2% year-over-year to -$112.6 million in Q1 2026; TTM through Mar 2026 was -$33.0 million, a 151.74% decrease from a year earlier, with the FY2025 full-year figure at $107.5 million, up 126.4% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$112.6 million, down from $22.4 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for IPSC reached as high as $39.2 million in Q3 2024 and fell as low as -$112.6 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged $5.3 million across 5 years, with a median of $18.6 million in 2023.
• On a YoY basis, Cash from Investing Activities climbed as much as 829.55% in 2024 and fell as far as 585.57% in 2024.
• Year by year, Cash from Investing Activities stood at -$4.3 million in 2022, then jumped by 535.36% to $18.6 million in 2023, then soared by 64.52% to $30.6 million in 2024, then retreated by 26.94% to $22.4 million in 2025, then slumped by 603.62% to -$112.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$112.6 million in Q1 2026, $22.4 million in Q4 2025, and $24.7 million in Q3 2025.